1. Post-Vaccination Delivery of CpG ODNs Enhances the Th2-Associated Protective Immunity of the Smallpox DNA Vaccine.
- Author
-
Lee MH, Choi HS, Kim NY, Sim E, Choi JY, Hong S, Shin YK, Yu CH, Gu SH, Song DH, Hur GH, and Shin S
- Subjects
- Animals, Mice, Female, Vaccination methods, Vaccinia virus genetics, Vaccinia virus immunology, Antibodies, Viral immunology, Toll-Like Receptor 9 immunology, Vaccines, DNA immunology, Vaccines, DNA administration & dosage, Mice, Inbred BALB C, Oligodeoxyribonucleotides immunology, Oligodeoxyribonucleotides administration & dosage, Smallpox Vaccine immunology, Smallpox Vaccine administration & dosage, Smallpox Vaccine genetics, Adjuvants, Immunologic administration & dosage, Th2 Cells immunology, Smallpox prevention & control, Smallpox immunology
- Abstract
Potential threat of smallpox bioterrorism and concerns related to the adverse effects of currently licensed live-virus vaccines suggest the need to develop novel vaccines with better efficacy against smallpox. Use of DNA vaccines containing specific antigen-encoding plasmids prevents the risks associated with live-virus vaccines, offering a promising alternative to conventional smallpox vaccines. In this study, we investigated the efficiency of toll-like receptor (TLR) ligands in enhancing the immunogenicity of smallpox DNA vaccines. BALB/c mice were immunized with a DNA vaccine encoding the vaccinia virus L1R protein, along with the cytosine-phosphate-guanine (CpG) motif as a vaccine adjuvant, and their immune response was analyzed. Administration of B-type CpG oligodeoxynucleotides (ODNs) as TLR9 ligands 24 h after DNA vaccination enhanced the Th2-biased L1R-specific antibody immunity in mice. Moreover, B-type CpG ODNs improved the protective effects of the DNA vaccine against the lethal Orthopoxvirus challenge. Therefore, use of L1R DNA vaccines with CpG ODNs as adjuvants is a promising approach to achieve effective immunogenicity against smallpox infection., (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF